PHARMACODYNAMICS SECTION.

12.2 Pharmacodynamics. The pharmacodynamic effects of OXLUMO have been evaluated in adult and pediatric patients with PH1 across range of doses and dosing frequency. Dose-dependent reductions in urinary oxalate levels were observed, resulting in the selection of the recommended body weight-based loading and maintenance dosing regimens. With the recommended dosing regimens, onset of effect was observed within two weeks after the first dose and maximal reductions in urinary oxalate were observed by Month and persisted with continued use of OXLUMO maintenance dosage [see Figures and in Clinical Studies (14.1, 14.2)] . Cardiac ElectrophysiologyAt the recommended dose, OXLUMO does not lead to clinically relevant QT interval prolongation.

ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. The most common adverse reaction (reported in >=20% of patients) is injection site reactions. 6.1) To report SUSPECTED ADVERSE REACTIONS, contact Alnylam Pharmaceuticals at 1-877-256-9526 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.. 6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The data reflect placebo-controlled and open-label clinical studies in 77 patients with PH1 (including 56 pediatric patients). Patients ranged in age from months to 61 years at first dose. The median duration of exposure was 9.1 months (range 1.9 to 21.7 months). Overall, 58 patients were treated for at least months, and 18 patients for at least 12 months.In the randomized, placebo-controlled, double-blind study ILLUMINATE-A in pediatric and adult patients with PH1 aged to 61 years, 26 patients received OXLUMO and 13 patients received placebo. Of these, 25 patients received >=5 months of treatment. The most common (>=20%) adverse reaction reported was injection site reaction. Injection site reactions occurred throughout the study period and included erythema, pain, pruritus, and swelling. These symptoms were generally mild and resolved within one day of the injection and did not lead to discontinuation of treatment.In the single-arm study (ILLUMINATE-B) in patients with PH1 who are <6 years of age, the safety profile observed was similar to that seen in ILLUMINATE-A [see Clinical Studies (14)] Table 2. Adverse Reactions Reported in at Least 10% of Patients Treated with OXLUMO and that Occurred at Least 5% More Frequently than in Patients Treated with Placebo in ILLUMINATE-A during the 6-Month Double-Blind PeriodAdverse ReactionOXLUMO N=26 (%) Placebo N=13 (%) Injection site reaction10 (38)0 (0)Abdominal pain Grouped term includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort (15)1 (8). 6.2 Immunogenicity. As with all oligonucleotides, including OXLUMO, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.Across all clinical studies in the lumasiran development program, including patients with PH1 and healthy volunteers dosed with OXLUMO, of 100 (6%) lumasiran-treated individuals with mean follow-up duration of 8.9 months, tested positive for anti-drug antibodies (ADA), as early as from Day 29. No clinically significant differences in the safety, pharmacokinetic, or pharmacodynamic profiles of lumasiran were observed in patients who tested positive for anti-lumasiran antibody.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies to assess carcinogenic risk of lumasiran have not been conducted.Lumasiran was not genotoxic in an in vitro bacterial reverse mutation (Ames) assay, in the in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, or the in vivo micronucleus assay in rats.Administration of lumasiran by weekly subcutaneous doses of 0, 5, 15, and 50 mg/kg in male and female rats prior to and during mating, and continuing in females once on Day of presumed gestation resulted in no adverse effects upon the male or female fertility endpoints evaluated.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.1 Mechanism of Action. Lumasiran reduces levels of glycolate oxidase (GO) enzyme by targeting the hydroxyacid oxidase ( HAO1) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, substrate for oxalate production. As the GO enzyme is upstream of the deficient alanine:glyoxylate aminotransferase (AGT) enzyme that causes PH1, the mechanism of action of lumasiran is independent of the underlying AGXT gene mutation. OXLUMO is not expected to be effective in primary hyperoxaluria type (PH2) or type (PH3) because its mechanism of action does not affect the metabolic pathways causing hyperoxaluria in PH2 and PH3. 12.2 Pharmacodynamics. The pharmacodynamic effects of OXLUMO have been evaluated in adult and pediatric patients with PH1 across range of doses and dosing frequency. Dose-dependent reductions in urinary oxalate levels were observed, resulting in the selection of the recommended body weight-based loading and maintenance dosing regimens. With the recommended dosing regimens, onset of effect was observed within two weeks after the first dose and maximal reductions in urinary oxalate were observed by Month and persisted with continued use of OXLUMO maintenance dosage [see Figures and in Clinical Studies (14.1, 14.2)] . Cardiac ElectrophysiologyAt the recommended dose, OXLUMO does not lead to clinically relevant QT interval prolongation.. 12.3 Pharmacokinetics. The pharmacokinetic (PK) properties of OXLUMO were evaluated following administration of single and multiple dosages in patients with PH1 as summarized in Table 3.Table 3. Pharmacokinetic Parameters of LumasiranLumasiranC max maximum plasma concentration; AUC 0-last area under the plasma concentration-time curve from time of administration (0) to the last measurable time point (last); max time to maximum concentration; Vd/F apparent volume of distribution; CV coefficient of variation; CL/F apparent clearance. General InformationSteady-State ExposureC max [Median (Range)] 462 (38.5 to 1500) ng/mLAUC 0-last [Median (Range)] 6810 (2890 to 10700) ngh/mL Dose ProportionalityLumasiran exhibited an approximately dose proportional increase in plasma exposure following single subcutaneous doses ranging from 0.3 to mg/kg.Lumasiran exhibited time-independent pharmacokinetics with multiple doses of and mg/kg once monthly or mg/kg quarterly. AccumulationNo accumulation of lumasiran was observed in plasma after repeated monthly or quarterly dosing.AbsorptionT max [Median (Range)] (0.5 to 12) hoursDistribution Lumasiran distributes primarily to the liver after subcutaneous administration. Estimated Vd/F4.9 Protein Binding85%Elimination Half-Life (Mean (%CV)])5.2 (47%) hours Estimated CL/F26.5 L/hourMetabolism Primary PathwayLumasiran is metabolized by endo- and exonucleases to oligonucleotides of shorter lengths.Excretion Primary PathwayLess than 26% of the administered dose of lumasiran is excreted unchanged into the urine within 24 hours with the rest excreted as inactive metabolite.. Lumasiran exhibited an approximately dose proportional increase in plasma exposure following single subcutaneous doses ranging from 0.3 to mg/kg.. Lumasiran exhibited time-independent pharmacokinetics with multiple doses of and mg/kg once monthly or mg/kg quarterly.. No accumulation of lumasiran was observed in plasma after repeated monthly or quarterly dosing.. Specific PopulationsNo clinically significant differences in the pharmacokinetics or pharmacodynamics of lumasiran were observed based on age (4 months to 65 years old), sex, race/ethnicity, eGFR 30 to 90 mL/min/1.73 2, or mild to moderate hepatic impairment (total bilirubin <= ULN and AST ULN; or total bilirubin <= 3x ULN). The effect of eGFR 30 mL/min/1.73 2 or dialysis, or severe hepatic impairment on the pharmacokinetics of lumasiran is unknown. Body WeightIn children <20 kg, lumasiran max was twice as high due to the higher mg/kg dose and faster absorption rate. At the approved recommended dosage, lumasiran AUC was similar across the 6.2 kg to 110 kg body weight range [see Dosage and Administration (2.1)] . Drug Interaction Studies. Clinical StudiesNo clinical studies evaluating the drug interaction potential of lumasiran have been conducted. Concomitant use of pyridoxine (vitamin B6) did not influence the pharmacodynamics or pharmacokinetics of lumasiran.. In Vitro StudiesIn vitro studies indicate that lumasiran is not substrate or an inhibitor of cytochrome P450 (CYP) enzymes. Lumasiran is not expected to induce CYP enzymes or modulate the activities of drug transporters.

CLINICAL STUDIES SECTION.

14 CLINICAL STUDIES. 14.1ILLUMINATE-A. ILLUMINATE-A was randomized, double-blind trial comparing lumasiran and placebo in 39 patients years of age and older with PH1 and an eGFR >=30 mL/min/1.73 2 (ILLUMINATE-A; NCT03681184). Patients received loading doses of mg/kg OXLUMO (N=26) or placebo (N=13) administered once monthly, followed by quarterly maintenance doses of mg/kg OXLUMO or placebo [see Dosage and Administration (2.1)] The median age was 15 years (range to 61 years), 67% were male, and 77% were White. At baseline, the median 24-hour urinary oxalate excretion corrected for body surface area (BSA) was 1.7 mmol/24 h/1.73 2, the median plasma oxalate level was 13.1 umol/L, 33% of patients had eGFR >=90 mL/min/1.73 2, 49% had eGFR of 60 to <90 mL/min/1.73 2, and 18% had eGFR 30 to <60 mL/min/1.73 2, 56% were on pyridoxine, and 85% reported history of symptomatic kidney stone events. The primary endpoint was the percent reduction from baseline in 24-hour urinary oxalate excretion corrected for BSA averaged over Months through 6. The LS mean percent change from baseline in 24-hour urinary oxalate in the OXLUMO group was -65% (95% CI: -71, -59) compared with -12% (95% CI: -20, -4) in the placebo group, resulting in between-group LS mean difference of 53% (95% CI: 45, 62; p<0.0001) [Figure 1].Figure 1. ILLUMINATE-A: Percent Change from Baseline in 24-hour Urinary Oxalate by MonthAbbreviations: SEM standard error of mean. Results are plotted as mean (+-SEM) of percent change from baseline. By Month 6, 52% (95% CI: 31, 72) of patients treated with OXLUMO achieved normal 24-hour urinary oxalate corrected for BSA (<=0.514 mmol/24 hr/1.73 2) compared to 0% (95% CI: 0, 25) placebo-treated patients (p=0.001). Figure 1. 14.2ILLUMINATE-B. ILLUMINATE-B was single-arm study in 18 patients <6 years of age with PH1 and an eGFR >45 mL/min/1.73 2 for patients >=12 months of age or normal serum creatinine for patients <12 months of age (ILLUMINATE-B; NCT03905694). Efficacy analyses included the first 16 patients who received months of treatment with OXLUMO. Dosing was based on body weight [see Dosage and Administration (2.1)] The median age was 47 months (range to 74 months), 56% were female, and 88% were White. Three patients were less than 10 kg, 11 were 10 kg to 20 kg, and were >= 20 kg. The median spot urinary oxalate:creatinine ratio at baseline was 0.47 mmol/mmol.The primary endpoint was the percent reduction from baseline in spot urinary oxalate:creatinine ratio averaged over Months through 6. Patients treated with OXLUMO achieved reduction in spot urinary oxalate:creatinine ratio from baseline of 71% (95% CI: 65, 77) [Figure 2].Figure 2.ILLUMINATE-B: Percent Change from Baseline in Spot Urinary Oxalate:Creatinine Ratio by MonthAbbreviations: SEM standard error of mean. Results are plotted as mean (+-SEM) of percent change from baseline. Figure 2.

CLINICAL TRIALS EXPERIENCE SECTION.

6.1 Clinical Trials Experience. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.The data reflect placebo-controlled and open-label clinical studies in 77 patients with PH1 (including 56 pediatric patients). Patients ranged in age from months to 61 years at first dose. The median duration of exposure was 9.1 months (range 1.9 to 21.7 months). Overall, 58 patients were treated for at least months, and 18 patients for at least 12 months.In the randomized, placebo-controlled, double-blind study ILLUMINATE-A in pediatric and adult patients with PH1 aged to 61 years, 26 patients received OXLUMO and 13 patients received placebo. Of these, 25 patients received >=5 months of treatment. The most common (>=20%) adverse reaction reported was injection site reaction. Injection site reactions occurred throughout the study period and included erythema, pain, pruritus, and swelling. These symptoms were generally mild and resolved within one day of the injection and did not lead to discontinuation of treatment.In the single-arm study (ILLUMINATE-B) in patients with PH1 who are <6 years of age, the safety profile observed was similar to that seen in ILLUMINATE-A [see Clinical Studies (14)] Table 2. Adverse Reactions Reported in at Least 10% of Patients Treated with OXLUMO and that Occurred at Least 5% More Frequently than in Patients Treated with Placebo in ILLUMINATE-A during the 6-Month Double-Blind PeriodAdverse ReactionOXLUMO N=26 (%) Placebo N=13 (%) Injection site reaction10 (38)0 (0)Abdominal pain Grouped term includes abdominal pain, abdominal pain upper, abdominal pain lower, and abdominal discomfort (15)1 (8).

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. None.. None. 4) None. 4).

DESCRIPTION SECTION.

11 DESCRIPTION. OXLUMO injection contains lumasiran, HAO1-directed double-stranded small interfering ribonucleic acid (siRNA), covalently linked to ligand containing N-acetylgalactosamine (GalNAc). The structural formula of lumasiran sodium is presented below:The molecular formula of lumasiran sodium is 530H 669F 10N 173O 320P 43S 6Na 43 and the molecular weight is 17,286 Da. OXLUMO is supplied as sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous administration containing the equivalent of 94.5 mg of lumasiran (provided as lumasiran sodium) in 0.5 mL of water for injection and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7.0.. Chemical Structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. The recommended dose of OXLUMO by subcutaneous injection is based on body weight. 2.1) Body WeightLoading DoseMaintenance Dose (begin month after the last loading dose) less than 10 kg6 mg/kg once monthly for doses3 mg/kg once monthly10 kg to less than 20 kg6 mg/kg once monthly for doses6 mg/kg once every months (quarterly)20 kg and above3 mg/kg once monthly for doses3 mg/kg once every months (quarterly)See Full Prescribing Information for important preparation and administration instructions. 2.2) The recommended dose of OXLUMO by subcutaneous injection is based on body weight. 2.1) 2.1Recommended Dosage. The recommended dosing regimen of OXLUMO consists of loading doses followed by maintenance doses administered subcutaneously as shown in Table 1.Dosing is based on actual body weight.Table 1. OXLUMO Weight-Based Dosing RegimenBody WeightLoading DoseMaintenance Dose (begin month after the last loading dose) Less than 10 kg6 mg/kg once monthly for doses3 mg/kg once monthly10 kg to less than 20 kg6 mg/kg once monthly for doses6 mg/kg once every months (quarterly)20 kg and above3 mg/kg once monthly for doses3 mg/kg once every months (quarterly). Missed DoseIf dose is delayed or missed, administer OXLUMO as soon as possible. Resume prescribed monthly or quarterly dosing, from the most recently administered dose.. 2.2Administration Instructions. OXLUMO is intended for subcutaneous use and should be administered by healthcare professional.Visually inspect the drug product solution. Do not use if it contains particulate matter or if it is cloudy or discolored. OXLUMO is sterile, preservative-free, clear, colorless-to-yellow solution. It is supplied in single-dose vial, as ready-to-use solution that does not require additional reconstitution or dilution prior to administration.Use aseptic technique.Divide injection volumes greater than 1.5 mL equally into multiple syringes.For volumes less than 0.3 mL, sterile 0.3-mL syringe is recommended. If using 0.3 mL (30 unit) insulin syringe, 1-unit markings indicate 0.01 mL.Administer subcutaneous injection into the abdomen, thigh, or the side or back of the upper arms. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen. If injecting into the abdomen, avoid the area around the navel.If more than one injection is needed for single dose of OXLUMO, the injection sites should be at least cm apart. Discard unused portion of the drug.. Use aseptic technique.. Divide injection volumes greater than 1.5 mL equally into multiple syringes.. For volumes less than 0.3 mL, sterile 0.3-mL syringe is recommended. If using 0.3 mL (30 unit) insulin syringe, 1-unit markings indicate 0.01 mL.. Administer subcutaneous injection into the abdomen, thigh, or the side or back of the upper arms. Rotate injection sites. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen. If injecting into the abdomen, avoid the area around the navel.If more than one injection is needed for single dose of OXLUMO, the injection sites should be at least cm apart. If injecting into the abdomen, avoid the area around the navel.. If more than one injection is needed for single dose of OXLUMO, the injection sites should be at least cm apart.. Discard unused portion of the drug.

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. Injection: 94.5 mg/0.5 mL clear, colorless-to-yellow solution in single-dose vial.. Injection: 94.5 mg/0.5 mL in single-dose vial. 3) Injection: 94.5 mg/0.5 mL in single-dose vial. 3).

GERIATRIC USE SECTION.

8.5 Geriatric Use. Clinical studies of OXLUMO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.

HEPATIC IMPAIRMENT SUBSECTION.

8.6 Hepatic Impairment. No dose adjustment is recommended for patients with mild (total bilirubin upper limit of normal (ULN) to 1.5 ULN or AST ULN) or moderate hepatic impairment (total bilirubin >1.5-3 ULN with any AST). OXLUMO has not been studied in patients with severe hepatic impairment (total bilirubin >3 ULN with any AST) [see Clinical Pharmacology (12.3)].

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. 16.1How Supplied. OXLUMO is clear, colorless-to-yellow solution available in single-dose vials of 94.5 mg/0.5 mL in cartons containing one vial (NDC 71336-1002-1).. 16.2Storage and Handling. Store at 2C to 25C [36F to 77F].Store OXLUMO in its original container until ready for use.

IMMUNOGENICITY.

6.2 Immunogenicity. As with all oligonucleotides, including OXLUMO, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.Across all clinical studies in the lumasiran development program, including patients with PH1 and healthy volunteers dosed with OXLUMO, of 100 (6%) lumasiran-treated individuals with mean follow-up duration of 8.9 months, tested positive for anti-drug antibodies (ADA), as early as from Day 29. No clinically significant differences in the safety, pharmacokinetic, or pharmacodynamic profiles of lumasiran were observed in patients who tested positive for anti-lumasiran antibody.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE. OXLUMO is indicated for the treatment of primary hyperoxaluria type (PH1) to lower urinary oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1), Clinical Studies (14.1, 14.2)] . OXLUMO is HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type (PH1) to lower urinary oxalate levels in pediatric and adult patients. 1).

LACTATION SECTION.

8.2 Lactation. Risk SummaryThere are no data on the presence of OXLUMO in human milk, the effects on the breastfed child, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or from the underlying maternal condition.

MECHANISM OF ACTION SECTION.

12.1 Mechanism of Action. Lumasiran reduces levels of glycolate oxidase (GO) enzyme by targeting the hydroxyacid oxidase ( HAO1) messenger ribonucleic acid (mRNA) in hepatocytes through RNA interference. Decreased GO enzyme levels reduce the amount of available glyoxylate, substrate for oxalate production. As the GO enzyme is upstream of the deficient alanine:glyoxylate aminotransferase (AGT) enzyme that causes PH1, the mechanism of action of lumasiran is independent of the underlying AGXT gene mutation. OXLUMO is not expected to be effective in primary hyperoxaluria type (PH2) or type (PH3) because its mechanism of action does not affect the metabolic pathways causing hyperoxaluria in PH2 and PH3.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies to assess carcinogenic risk of lumasiran have not been conducted.Lumasiran was not genotoxic in an in vitro bacterial reverse mutation (Ames) assay, in the in vitro chromosomal aberration assay in cultured human peripheral blood lymphocytes, or the in vivo micronucleus assay in rats.Administration of lumasiran by weekly subcutaneous doses of 0, 5, 15, and 50 mg/kg in male and female rats prior to and during mating, and continuing in females once on Day of presumed gestation resulted in no adverse effects upon the male or female fertility endpoints evaluated.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL 0.5 mL Vial Carton. NDC 71336-1002-1OXLUMO(TM) (lumasiran) injection 94.5 mg/0.5 mLFor Subcutaneous Injection by Healthcare Professional Only Single-dose vial Discard unused portion Rx Only. PRINCIPAL DISPLAY PANEL 0.5 mL Vial Carton.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. The safety and effectiveness of OXLUMO have been established in pediatric patients aged birth and older. Use of OXLUMO in these age groups is supported by evidence from an adequate and well controlled study of OXLUMO in children years or older and adults with PH1 (ILLUMINATE-A), and single-arm clinical study in children less than years of age with PH1 (ILLUMINATE-B) [see Adverse Reactions (6.1), Clinical Studies (14)].

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. The pharmacokinetic (PK) properties of OXLUMO were evaluated following administration of single and multiple dosages in patients with PH1 as summarized in Table 3.Table 3. Pharmacokinetic Parameters of LumasiranLumasiranC max maximum plasma concentration; AUC 0-last area under the plasma concentration-time curve from time of administration (0) to the last measurable time point (last); max time to maximum concentration; Vd/F apparent volume of distribution; CV coefficient of variation; CL/F apparent clearance. General InformationSteady-State ExposureC max [Median (Range)] 462 (38.5 to 1500) ng/mLAUC 0-last [Median (Range)] 6810 (2890 to 10700) ngh/mL Dose ProportionalityLumasiran exhibited an approximately dose proportional increase in plasma exposure following single subcutaneous doses ranging from 0.3 to mg/kg.Lumasiran exhibited time-independent pharmacokinetics with multiple doses of and mg/kg once monthly or mg/kg quarterly. AccumulationNo accumulation of lumasiran was observed in plasma after repeated monthly or quarterly dosing.AbsorptionT max [Median (Range)] (0.5 to 12) hoursDistribution Lumasiran distributes primarily to the liver after subcutaneous administration. Estimated Vd/F4.9 Protein Binding85%Elimination Half-Life (Mean (%CV)])5.2 (47%) hours Estimated CL/F26.5 L/hourMetabolism Primary PathwayLumasiran is metabolized by endo- and exonucleases to oligonucleotides of shorter lengths.Excretion Primary PathwayLess than 26% of the administered dose of lumasiran is excreted unchanged into the urine within 24 hours with the rest excreted as inactive metabolite.. Lumasiran exhibited an approximately dose proportional increase in plasma exposure following single subcutaneous doses ranging from 0.3 to mg/kg.. Lumasiran exhibited time-independent pharmacokinetics with multiple doses of and mg/kg once monthly or mg/kg quarterly.. No accumulation of lumasiran was observed in plasma after repeated monthly or quarterly dosing.. Specific PopulationsNo clinically significant differences in the pharmacokinetics or pharmacodynamics of lumasiran were observed based on age (4 months to 65 years old), sex, race/ethnicity, eGFR 30 to 90 mL/min/1.73 2, or mild to moderate hepatic impairment (total bilirubin <= ULN and AST ULN; or total bilirubin <= 3x ULN). The effect of eGFR 30 mL/min/1.73 2 or dialysis, or severe hepatic impairment on the pharmacokinetics of lumasiran is unknown. Body WeightIn children <20 kg, lumasiran max was twice as high due to the higher mg/kg dose and faster absorption rate. At the approved recommended dosage, lumasiran AUC was similar across the 6.2 kg to 110 kg body weight range [see Dosage and Administration (2.1)] . Drug Interaction Studies. Clinical StudiesNo clinical studies evaluating the drug interaction potential of lumasiran have been conducted. Concomitant use of pyridoxine (vitamin B6) did not influence the pharmacodynamics or pharmacokinetics of lumasiran.. In Vitro StudiesIn vitro studies indicate that lumasiran is not substrate or an inhibitor of cytochrome P450 (CYP) enzymes. Lumasiran is not expected to induce CYP enzymes or modulate the activities of drug transporters.

PREGNANCY SECTION.

8.1 Pregnancy. Risk SummaryThere are no available data with the use of OXLUMO in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.No adverse effects on pregnancy or embryo-fetal development related to OXLUMO were observed in rats at 45 times and in rabbits at 90 times the maximum recommended human dose in women (see Data). The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.. Data. Animal DataIn an embryo-fetal development study in pregnant rats, lumasiran was administered subcutaneously at doses of 3, 10, and 30 mg/kg/day during organogenesis (gestational days 6-17). Administration of lumasiran resulted in no effects on embryo-fetal survival or fetal body weights and no lumasiran-related fetal malformations were observed. The 30-mg/kg/day dose in rats is 45 times the maximum recommended human dose (MRHD) for women of mg/kg/month normalized to 0.1 mg/kg/day, based on body surface area. In an embryo-fetal development study in female rabbits, lumasiran was administered subcutaneously at doses of 3, 10, and 30 mg/kg/day during organogenesis (gestational days 7-19). There were decreases in maternal food consumption and decreases in maternal body weight gains at doses >=3 mg/kg/day. There were no lumasiran-related fetal findings identified at doses up to 30 mg/kg/day (90 times the normalized MRHD based on body surface area).In postnatal development study, lumasiran administered subcutaneously to pregnant female rats on gestational days 7, 13, 19 and on lactation days 6, 12, and 18 through weaning at doses up to 50 mg/kg did not produce maternal toxicity or developmental effects in the offspring.

RENAL IMPAIRMENT SUBSECTION.

8.7 Renal Impairment. No dose adjustment is necessary in patients with an estimated glomerular filtration rate (eGFR) of >=30 mL/min/1.73 2 [see Clinical Pharmacology (12.3), Clinical Studies (14)] OXLUMO has not been studied in patients with an eGFR <30 mL/min/1.73 2 or patients on dialysis [see Clinical Pharmacology (12.3)].

SPL UNCLASSIFIED SECTION.

2.1Recommended Dosage. The recommended dosing regimen of OXLUMO consists of loading doses followed by maintenance doses administered subcutaneously as shown in Table 1.Dosing is based on actual body weight.Table 1. OXLUMO Weight-Based Dosing RegimenBody WeightLoading DoseMaintenance Dose (begin month after the last loading dose) Less than 10 kg6 mg/kg once monthly for doses3 mg/kg once monthly10 kg to less than 20 kg6 mg/kg once monthly for doses6 mg/kg once every months (quarterly)20 kg and above3 mg/kg once monthly for doses3 mg/kg once every months (quarterly). Missed DoseIf dose is delayed or missed, administer OXLUMO as soon as possible. Resume prescribed monthly or quarterly dosing, from the most recently administered dose.

STORAGE AND HANDLING SECTION.

16.2Storage and Handling. Store at 2C to 25C [36F to 77F].Store OXLUMO in its original container until ready for use.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. 8.1 Pregnancy. Risk SummaryThere are no available data with the use of OXLUMO in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.No adverse effects on pregnancy or embryo-fetal development related to OXLUMO were observed in rats at 45 times and in rabbits at 90 times the maximum recommended human dose in women (see Data). The estimated background risk of major birth defects and miscarriage in the indicated population is unknown. All pregnancies have background risk of birth defect, loss or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.. Data. Animal DataIn an embryo-fetal development study in pregnant rats, lumasiran was administered subcutaneously at doses of 3, 10, and 30 mg/kg/day during organogenesis (gestational days 6-17). Administration of lumasiran resulted in no effects on embryo-fetal survival or fetal body weights and no lumasiran-related fetal malformations were observed. The 30-mg/kg/day dose in rats is 45 times the maximum recommended human dose (MRHD) for women of mg/kg/month normalized to 0.1 mg/kg/day, based on body surface area. In an embryo-fetal development study in female rabbits, lumasiran was administered subcutaneously at doses of 3, 10, and 30 mg/kg/day during organogenesis (gestational days 7-19). There were decreases in maternal food consumption and decreases in maternal body weight gains at doses >=3 mg/kg/day. There were no lumasiran-related fetal findings identified at doses up to 30 mg/kg/day (90 times the normalized MRHD based on body surface area).In postnatal development study, lumasiran administered subcutaneously to pregnant female rats on gestational days 7, 13, 19 and on lactation days 6, 12, and 18 through weaning at doses up to 50 mg/kg did not produce maternal toxicity or developmental effects in the offspring.. 8.2 Lactation. Risk SummaryThere are no data on the presence of OXLUMO in human milk, the effects on the breastfed child, or the effects of the drug on milk production. The developmental and health benefits of breastfeeding should be considered along with the mothers clinical need for OXLUMO and any potential adverse effects on the breastfed child from OXLUMO or from the underlying maternal condition.. 8.4 Pediatric Use. The safety and effectiveness of OXLUMO have been established in pediatric patients aged birth and older. Use of OXLUMO in these age groups is supported by evidence from an adequate and well controlled study of OXLUMO in children years or older and adults with PH1 (ILLUMINATE-A), and single-arm clinical study in children less than years of age with PH1 (ILLUMINATE-B) [see Adverse Reactions (6.1), Clinical Studies (14)] . 8.5 Geriatric Use. Clinical studies of OXLUMO did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.. 8.6 Hepatic Impairment. No dose adjustment is recommended for patients with mild (total bilirubin upper limit of normal (ULN) to 1.5 ULN or AST ULN) or moderate hepatic impairment (total bilirubin >1.5-3 ULN with any AST). OXLUMO has not been studied in patients with severe hepatic impairment (total bilirubin >3 ULN with any AST) [see Clinical Pharmacology (12.3)] . 8.7 Renal Impairment. No dose adjustment is necessary in patients with an estimated glomerular filtration rate (eGFR) of >=30 mL/min/1.73 2 [see Clinical Pharmacology (12.3), Clinical Studies (14)] OXLUMO has not been studied in patients with an eGFR <30 mL/min/1.73 2 or patients on dialysis [see Clinical Pharmacology (12.3)].

RECENT MAJOR CHANGES SECTION.

Indications and Usage (1)10/2022Dosage and Administration (2.1)10/2022.